Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Plan B Approval Clears The Way For Von Eschenbach Confirmation

Executive Summary

FDA's decision to approve the emergency contraceptive Plan B for over-the-counter sale to women age 18 and older opens the door to a vote on FDA Acting Commissioner Andrew von Eschenbach's nomination to the permanent post

You may also be interested in...



Von Eschenbach Receiving HELP With GOP Nomination Hurdles

Senate Health, Education, Labor & Pensions committee members are working to end Republican holds on the nomination of FDA Acting Commissioner Andrew von Eschenbach to the permanent post

Von Eschenbach Receiving HELP With GOP Nomination Hurdles

Senate Health, Education, Labor & Pensions committee members are working to end Republican holds on the nomination of FDA Acting Commissioner Andrew von Eschenbach to the permanent post

Health Committee to vote on von Eschenbach

Senate Health Committee is scheduled to vote Sept. 20 on the nomination of Andrew von Eschenbach to be permanent commissioner of FDA, despite the prospect of future holds. Sen. David Vitter (R-La.) has threatened a hold to push for a drug importation program, while Sen. Jim DeMint (R-S.C.) may use a hold to protest the continued marketing of Danco Laboratories' abortifacient Mifeprex. Democratic Sens. Hillary Clinton (N.Y.) and Patty Murray (Wash.) recently released a hold on von Eschenbach following FDA's approval of the morning-after pill Plan B for OTC use (1"The Pink Sheet" Aug. 28, 2006, p. 9)...

Related Content

UsernamePublicRestriction

Register

ID020288

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel